Robert H. Liebross

664 total citations
18 papers, 474 citations indexed

About

Robert H. Liebross is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Robert H. Liebross has authored 18 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 3 papers in Surgery. Recurrent topics in Robert H. Liebross's work include Multiple Myeloma Research and Treatments (3 papers), Chromium effects and bioremediation (3 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). Robert H. Liebross is often cited by papers focused on Multiple Myeloma Research and Treatments (3 papers), Chromium effects and bioremediation (3 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). Robert H. Liebross collaborates with scholars based in United States. Robert H. Liebross's co-authors include Chul S. Ha, Karen E. Wetterhahn, Donna M. Weber, James D. Cox, Kay Delasalle, Raymond Alexanian, Donna Weber, James D. Cox, John S. Boswell and Andrew C. von Eschenbach and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Robert H. Liebross

16 papers receiving 454 citations

Peers

Robert H. Liebross

HEMAT

ONCOL

MB

HTM

GENET

Agnieszka Szymczyk Poland

Patrick J. Kerzic United States

Hyeoung-Joon Kim South Korea

Grace H. Tang Canada

Michalis Michael Greece

D. Baer United States

Martin Lombard United Kingdom

G. Laurent France

Debargha Basuli United States

Anton Roth Poland

Agnieszka Szymczyk Poland

Robert H. Liebross

94 ×0.3

HEMAT

115 ×0.7

ONCOL

83 ×0.8

MB

54 ×0.6

HTM

86 ×1.0

GENET

Citations per year, relative to Robert H. Liebross Robert H. Liebross (= 1×) peers Agnieszka Szymczyk

Countries citing papers authored by Robert H. Liebross

Since Specialization

Citations

This map shows the geographic impact of Robert H. Liebross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert H. Liebross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert H. Liebross more than expected).

Fields of papers citing papers by Robert H. Liebross

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert H. Liebross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert H. Liebross. The network helps show where Robert H. Liebross may publish in the future.

Co-authorship network of co-authors of Robert H. Liebross

This figure shows the co-authorship network connecting the top 25 collaborators of Robert H. Liebross. A scholar is included among the top collaborators of Robert H. Liebross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert H. Liebross. Robert H. Liebross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

1.

Liebross, Robert H., et al.. (2025). Concurrent pembrozulimab and radiation treatments in the management of locally advanced bladder cancer in cisplatin-ineligible patients.. Journal of Clinical Oncology. 43(5_suppl). 817–817.

2.

Rowe, Michael, Robert H. Liebross, Chad Davis, et al.. (2020). Neoadjuvant gemcitabine and nab-paclitaxel followed by concurrent capecitabine/radiation in borderline resectable (BR) pancreatic cancer: A single-institution experience.. Journal of Clinical Oncology. 38(4_suppl). 718–718. 1 indexed citations

3.

Reichard, Chad A., Michael C. Large, Robert H. Liebross, et al.. (2020). Pembrolizumab and concurrent radiation is an effective regimen for muscle invasive bladder cancer.. Journal of Clinical Oncology. 38(15_suppl). e17020–e17020.

4.

Davis, Chad, Robert H. Liebross, Thomas Dugan, et al.. (2016). Neoadjuvant gemcitabine and nab-paclitaxel followed by concurrent capecitabine and radiation efficacy in borderline resectable (BR) pancreatic cancer.. Journal of Clinical Oncology. 34(15_suppl). e15698–e15698. 1 indexed citations

5.

Freeman, Richard K., Susan Storey, Anthony J. Ascioti, et al.. (2014). Lung cancer screening in high-risk individuals with annual low-dose chest CT in a community setting.. Journal of Clinical Oncology. 32(15_suppl). e12529–e12529. 1 indexed citations

6.

Liebross, Robert H., et al.. (2011). A Feasibility Trial of Concurrent Radiation, Temozolomide, and Bevacizumab Followed by Temozolomide and Bevacizumab for Resectable and Unresectable Glioblastoma Multiforme of the Brain. International Journal of Radiation Oncology*Biology*Physics. 81(2). S275–S275. 1 indexed citations

7.

Liebross, Robert H., Susan M. Schultz, Troy D. Payner, et al.. (2009). A Feasibility Trial of Concurrent Radiation, Temozolomide, and Bevacizumab followed by Temozolomide and Bevacizumab for Resectable and Unresectable Glioblastoma Multiforme of the Brain. International Journal of Radiation Oncology*Biology*Physics. 75(3). S125–S125. 2 indexed citations

8.

Liebross, Robert H., George Starkschall, Pei‐Fong Wong, et al.. (2002). The effect of titanium stabilization rods on spinal cord radiation dose. Medical dosimetry. 27(1). 21–24. 20 indexed citations

9.

Liebross, Robert H., et al.. (1999). Clinical course of solitary extramedullary plasmacytoma. Radiotherapy and Oncology. 52(3). 245–249. 187 indexed citations

10.

Liebross, Robert H., Alan Pollack, Scott P. Lankford, et al.. (1999). Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy. Cancer. 85(7). 1577–1585. 1 indexed citations

11.

Liebross, Robert H., Alan Pollack, Scott P. Lankford, et al.. (1999). Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy. Cancer. 85(7). 1577–1585. 20 indexed citations

12.

Liebross, Robert H., Chul S. Ha, James D. Cox, et al.. (1998). Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 41(5). 1063–1067. 117 indexed citations

13.

Liebross, Robert H., Alan Pollack, Scott P. Lankford, Andrew C. von Eschenbach, & Gunar K. Zagars. (1998). Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy. Urology. 52(4). 647–652. 11 indexed citations

14.

Liebross, Robert H., Chul S. Ha, James D. Cox, et al.. (1998). Comparison between solitary bone and extramedullary plasmacytoma following radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 42(1). 346–346. 1 indexed citations

15.

Liebross, Robert H., William H. Morrison, Adam S. Garden, & K. Kian Ang. (1997). 50 Mucosal melanoma of the head and neck. International Journal of Radiation Oncology*Biology*Physics. 39(2). 159–159. 5 indexed citations

16.

Liebross, Robert H. & Karen E. Wetterhahn. (1992). In vivo formation of chromium(V) in chick embryo liver and red blood cells. Carcinogenesis. 13(11). 2113–2120. 16 indexed citations

17.

Boswell, John S., et al.. (1991). Activation of chromium(VI) by thiols results in chromium(V) formation, chromium binding to DNA and altered DNA conformation. Carcinogenesis. 12(4). 551–561. 69 indexed citations

18.

Liebross, Robert H. & Karen E. Wetterhahn. (1990). In vivo formation of chromium(V) in chick embryo red blood cells. Chemical Research in Toxicology. 3(5). 401–403. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact